The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis. Mice with a heterozygous APC Min mutation develop multiple intestinal neoplasia (Min) leading to premature death. Early in colorectal carcinogenesis, APC Min/ þ mice show enhanced Akt-mammalian target of rapamycin (mTOR) signaling, which is paralleled by upregulation of oncogenic K þ channels. In this study, we tested the effect of mTOR inhibition with rapamycin on tumor formation in APC Min/ þ mice and evaluated ion channel regulation. We found that continuous long-term rapamycin treatment of APC Min/ þ mice dramatically inhibits intestinal neoplasia. Moreover, although untreated APC Min/ þ mice lose weight, experience intestinal bleeding and succumb to multiple neoplasia by 22.3±1.4 weeks of age, mice treated with rapamycin maintain stable weight and survive long term (39.6 ± 3.4 weeks), with more than 30% surviving >1 year. Impressively, abnormalities in colonic electrolyte transport typical for APC Min/ þ mice are abolished, along with the suppression of epithelial Na þ channel (ENaC) and oncogenic K þ ion channels BK, Elk1 and Erg1, both functionally and at mRNA levels. These results show that continuous prophylaxis by rapamycin markedly inhibits the development of APC mutation-related polyposis, and suggest a novel contributing mechanism of action through the blockade of intestinal oncogenic ion channels.
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Multiple intestinal neoplasia (Min) is a nonsense mutation in the murine APC gene, predisposing mice to multiple intestinal adenoma formation, like humans with similar germline mutations. Therefore, APC Min mice provide an excellent animal model to study intestinal tumorigenesis and its chemoprevention (Su et al., 1992; Moser et al., 1995; Swamy et al., 2006) . Heterozygous APC Min/ þ mice develop multiple intestinal tumors, anemia, splenomegaly, thrive less and typically die around week 20 (Fodde et al., 1994) . Besides the likely involvement of the Wnt-b-catenin pathway dysfunction, other signaling molecules have been implicated. A recent study has suggested that colonic polyposis in a similar mouse model (Apc
compound-mutant mice; Aoki et al. (2003) ) is linked to mammalian target of rapamycin (mTOR)-mediated chromosomal instability. Indeed, just before the completion of our study, it was reported for the first time that an mTOR inhibitor (RAD001) inhibits adenoma formation in Apc D716 mice (Fujishita et al., 2008) . It has also been reported that anaphase bridging in colon cancer cells is enhanced through the activation of mTOR by Akt, an effect that was suppressed by mTOR pathway inhibitors (Aoki et al., 2003) . Therefore, a clear rationale exists for therapeutically targeting mTOR to resist the effects of Min mutations in FAP.
From another mechanistic viewpoint, we have previously shown that the development of intestinal cancer is characterized by the expression of oncogenic K þ ion channels, such as voltage-gated K þ channels of the ether-a-go-go (Eag) family and large conductance Ca 2 þ -activated K þ channels Spitzner et al., 2007 Spitzner et al., , 2008 . Ion channels have been found to support the proliferation and development of cancer cells (Kunzelmann, 2005) . Furthermore, colonic changes in heterozygous APC Min/ þ animals are accompanied by a large increase in Na þ absorption and expression of epithelial Na þ channels (ENaC) . The fact that APC Min/ þ mice show upregulation of oncogenic K þ channels and enhanced Akt-mTOR activity leads to the hypothesis that rapamycin can correct this potentially oncogenic aberration.
In this study, APC
Min/ þ mice were put on a high-fat diet with or without (control food) rapamycin. Several factors affect rapamycin blood levels, including food fat content and strain background. Therefore, the amount of rapamycin incorporated into food pellets was empirically adjusted to reach therapeutic levels in this mouse strain-food combination. We found that mice fed high-fat rapamycin-containing (40 mg/kg sirolimus, Wyeth Pharmaceuticals, Collegeville, PA, USA) chow showed blood levels of 12±2 ng/ml rapamycin (n ¼ 66) and were thus, in the therapeutic range commonly used long-term in transplantation. There was no appreciable difference between the APC Min/ þ mice tested at the time of being killed and their wild-type (wt) siblings (14 ± 2 ng/ml, n ¼ 12 versus 12 ± 2 ng/ml, n ¼ 54, respectively). Although we cannot exclude the possibility that individual mice might have had slight variations in food uptake, affecting their daily dose, we indirectly monitored it by closely following each animal's weight. APC Min/ þ mice developed at 20 weeks of age multiple neoplasias in the small intestine, which were largely eliminated in mice under continuous rapamycin treatment (Figures 1a-d) . Polyps in the large intestine were infrequent in both control and rapamycin-treated mice, which is known to be the case in APC Min/ þ mice (Su et al., 1992; Swamy et al., 2006) ; in some cases, polyps did occur on the large intestine/anus and tended to be large in rapamycin-treated mice (Figure 1c , right panel). A routine macroscopic inspection of solid internal organs (such as the liver, pancreas, kidneys, lung, heart) showed no evident differences between groups.
However, a clear positive effect of rapamycin treatment was evident from at least three typical indirect parameters of disease progression in APC Min/ þ mice. First, spleens collected from control mice at 20 weeks of age showed the already well-described splenomegaly, whereas rapamycin-treated mice showed an essentially normal spleen size, similar to wt mice under rapamycin therapy (Figure 1e ). Second, control mice showed a dramatic decrease in hematocrit levels due to internal intestinal bleeding, but animals treated with rapamycin showed no significant decrease in hematocrit levels compared with wt mice (Figure 1f) . Third, as a result of polyp formation in APC Min/ þ mice, thriving is reduced and progressive weight loss is observed. In this study, weight loss in APC Min/ þ mice was largely attenuated by rapamycin treatment (Figure 2a) .
As a result of the consuming disease, APC Min/ þ animals died, on an average, at the age of 22.3±1.4 weeks ( Figure 2b ). However, survival was substantially normalized in rapamycin-treated mice (39.6 ± 3.4 weeks) to the point of only being marginally different from rapamycin-treated wt mice (50.1 ± 3.6, P ¼ 0.051). It is to be noted as well that 31% of rapamycin-treated mice survived for at least 1 year, which was considered to be the end of the experiment. Thus, rapamycin treatment has a pronounced therapeutic effect in APC Min/ þ mice, reverting animals to a near normal phenotype.
Mutations in the APC tumor-suppressor gene led to an increase in Wnt signaling, resulting in b-catenin stabilization and the activation of transcription factors that promote cancer development. As mTOR is integrated with Wnt signaling (Inoki et al., 2006) , we tested the effects of rapamycin on b-catenin expression in APC Min/ þ mice. Compared with normal intestinal tissue, b-catenin expression was increased in adenomatous polyps, as might be expected (Supplementary Figure 1) . Although rapamycin treatment did not seem to decrease the b-catenin baseline expression in the normal tissue, levels were not found to be increased in polyps from rapamycin-treated mice. Therefore, polyps that did manage to grow under mTOR inhibitor treatment were likely to be impaired in their capacity to upregulate key oncogenes that are under the control of b-catenin, at least partially explaining their delayed appearance.
We also studied the possible involvement of oncogenic ion channels in the observed effect. APC Min/ þ mice have an enhanced colonic Na þ absorption that even extends to the proximal colon . Interestingly, a previous report has shown that the expression of ENaC is regulated by a molecule downstream of mTOR, eukaryotic initiation factor (eIF4E) (Otulakowski et al., 2007) ; mTOR controls the phosphorylation of 4E-BP1, which inhibits eIF4E (Fingar et al., 2002; Koehl et al., 2005; Otulakowski et al., 2007) . Remarkably, in our experiments, abnormal expressions of both b-and g-ENaC were reverted to the normal levels found in wt animals by rapamycin treatment (Figure 3a) . Although a-ENaC is normally constitutively expressed and therefore was not upregulated in APC Min/ þ , rapamycin also significantly reduced the expression of this subunit. As it has been previously shown that electrogenic Na þ absorption by ENaC in fetal lung epithelia is dependent on mTOR (Otulakowski et al., 2007) , we measured Na þ transport in the colonic epithelium by applying the ENaC inhibitor amiloride. In these experiments, the effect of 20 mM amiloride on Na þ absorption was enhanced in APC Min/ þ mice when compared with wt animals, but was normalized in rapamycin-treated mice (Figures 3b-d) . The negative transepithelial voltage (V te ) that is due to amiloridesensitive Na þ absorption in the distal colon is largely enhanced in APC Min/ þ animals when compared with wt mice (left and middle trace of Figure 3b ). Treatment with rapamycin completely restored amiloride-sensitive Na þ absorption (right trace of Figure 3b ). The amiloride-inhibitable short-circuit currents of the distal colon (I sc-Amil-distal colon ) clearly indicate that the enhanced Na þ absorption in APC Min/ þ mice is normalized after treatment with rapamycin ( Figure 3c ). Even more impressive was the induction of Na þ absorption in the proximal colon (I sc-Amil-proximal colon ) in APC Min/ þ mice, which was almost abolished by rapamycin (Figure 3d ).
The expression of oncogenic K þ ion channels has been studied in human colon cancer and various cancer models in mice Spitzner et al., 2007) . APC Min/ þ mice have an upregulation of Ca 2 þ -activated (BK) K þ channels and voltage-gated K þ channels of the Eag family compared with control
Rapamycin suppresses neoplasia in APC Min/ þ mice GE Koehl et al animals ). An oncogenic role of these channels has been well established (Pardo et al., 2005) . In this study, a quantitative real-time PCR analysis of the APC Min/ þ mouse colon confirmed this observation of the Eag family channels by showing a significantly enhanced expression of Erg1 and an Figure 1 Rapamycin inhibits polyp formation in APC Min/ þ mice. APC Min/ þ mice (Jackson Laboratory, Bar Harbor, MA, USA) were bred in our facility for the experiments. Five-week-old offspring were started on a high-fat diet (complete chow containing 15% corn oil; SSNIFF, Soest, Germany) at libitum and randomized into control (no treatment) and rapamycin treatment groups. In the treatment group, 40 mg/kg rapamycin (sirolimus; Wyeth Pharmaceuticals, Collegeville, PA, USA) was admixed into the food pellets, as we have previously described (Koehl et al., 2006) . Rapamycin levels were determined in wild-type (wt) siblings by certified methods. Mice were weighed and monitored at least weekly for clinical symptoms of polyps, including rectal bleeding, rectal prolapse, reduced activity and weight loss. Age-matched wt siblings served as controls for potential rapamycin side effects. At the time of being killed (clinical complications, or age 52 weeks), blood was collected to measure hematocrit and rapamycin levels. Polyps in the small and large intestine were counted and the spleen was weighed. Animal experiments were ethically approved. Rapamycin suppresses neoplasia in APC Min/ þ mice GE Koehl et al upregulated Elk1 (Figure 4a ). Rapamycin treatment of APC Min/ þ mice caused a reduction in Erg1 and Elk1 expression, thus potentially reducing their oncogenic potential. As these channels are inhibited by the blocker astemizole (5 mM), the astemizole-sensitive transport (I scAstemizole ) that was upregulated in APC Min/ þ mice was completely normalized after rapamycin treatment (Figure 4b ).
The Ca 2 þ -dependent K þ channel (BK) was also analyzed. Both b1 (KCNMB1) and b4 (KCNMB4) subunits show an enhanced expression in APC Min/ þ mice . Our experiments show that the high mRNA levels of these two BK channel subunits in APC Min/ þ mice are completely downregulated and normalized by continuous rapamycin therapy (Figure 4c ). Normalization of mRNA levels was paralleled by correction of the functional defect; an activator of BK channels, NS1619 (10 mM), activated a much larger current (I sc -NS1619) in the colon of APC Min/ þ mice, which, again, was completely normalized after rapamycin treatment (Figure 4d ). Taken together, these results indicate that inhibition of mTOR signaling by rapamycin normalizes ion channel dysregulation in the gut that is associated with the APC Min/ þ phenotype. Our results clearly show that continuous treatment with maintainable rapamycin doses dramatically reduces the occurrence of polyps in APC Min/ þ mice, confirming the results of a similar study using RAD001, which was published at the time of completing this study (Fujishita et al., 2008) . Our current study goes further to show that the clinical status of these animals neared that of wt mice on long-term rapamycin. An overall beneficial effect of mTOR inhibition in APC Min/ þ mice was evident from their ability to maintain weight and not become chronically anemic. The fact that rapamycin treatment did not contribute to the development of anemia also indicates that the dose administered was not toxic, as overdosing of rapamycin can cause bone marrow suppression in humans (Gaber et al., 2008) . In addition, rapamycin was administered by incorporating it into their food pellets, and mice never received relatively high daily 'bolus' dosing, as was recently reported (Fujishita et al., 2008) . A low, continuous, dosing regime could provide an optimized treatment effect, while avoiding the most severe side effects of high peak levels. This idea is supported by our earlier studies showing that the antitumor effect of rapamycin decreases with high bolus dosing (Guba et al., 2005) . Dosing could be a critical factor if mTOR inhibitors are eventually used in FAP patients, who are often young and might need to take the medication life long.
It has been reported that APC Min/ þ mice show upregulated phosphoinositide-3 kinase-Akt signaling in intestinal tumors (Moran et al., 2004; Spitzner et al., 2008) , which is a main route of triggering mTOR. Besides this quite direct involvement of mTOR in tumor formation in the gut, APC mutations have also been related to alterations in Wnt-Akt-b-catenin signaling, which is commonly dysregulated in colorectal cancers (Fodde et al., 2001; Dihlmann et al., 2005) . As b-catenin is an effector molecule that affects the transcription of numerous key tumor-dependent proteins, we examined its expression in growing polyps. Rapamycin did not affect baseline b-catenin expression in neoplasms, but mice was significantly prolonged by rapamycin treatment (Po0.05). There was a difference only nearing statistical significance in the survival between rapamycin-treated mice and wt animals (P ¼ 0.051). Filled circles represent animals censored in the survival analysis before week 52, because of causes not related to polyp formation or treatment, including the presence of a tumor on the leg and death due to complications from blood collection. All surviving animals were censored at week 52 (end of experiment). The Kaplan-Meier survival curve was analyzed by mlog-rank test, followed by pairwise multiple comparison procedures (HolmSidak method), and was confirmed by pairwise log-rank tests. APC, adenomatous polyposis coli; wt, wild type.
Rapamycin suppresses neoplasia in APC Min/ þ mice GE Koehl et al tended to inhibit its upregulation. This shows that mTOR inhibition in APC Min/ þ animals is coupled to the Wnt-Akt-b-catenin pathway in vivo, and thus can influence tumor growth. Interestingly, a recent publication suggests that the relationship between b-catenin and mTOR may actually be of an opposite nature, whereby the absence of b-catenin results in decreased mTOR levels (Fujishita et al., 2008) . Although not a central focus of our study, a better understanding of the complex interactions between these signaling molecules should eventually bring more clarity to the mechanisms behind FAP. Min/ þ (gray bar) mice. Total RNA was isolated from crypt cells using standard techniques. For each RNA sample, a 1 mg aliquot was reverse transcribed into cDNA. Primer sets were designed for determining the expression levels of voltage-gated abg-ENaC . Real-time PCR was performed using the Quanti Tect SYBR Green PCR Kit (Qiagen, Hilden, Germany) and the Light Cycler system (Roche, Mannheim, Germany). (b) For Ussig chamber measurements, stripped colon was placed into an ice-cold Ringer solution. Tissues were measured in a perfused Ussig chamber under open circuit conditions, as described previously . Data were collected continuously using PowerLab (AD-Instruments, Melbourne, Australia). Values for transepithelial voltages (V te ) were referred to the serosal side of the epithelium. Transepithelial resistance (R te ) was determined by applying short (1 s) current pulses (DI ¼ 0.5 mA). R te and equivalent short-circuit currents (I SC ) were calculated according to Ohm's law (R te ¼ DV te /DI, I SC ¼ V te /R te ). The original recordings of the transepithelial voltage (V te ) and the effects of amiloride (20 mM) on Na þ absorption in the colonic epithelium of APC þ / þ , APC Min/ þ and rapamycin-treated APC Min/ þ mice are shown. The enhanced amiloride effect in the colon of APC Min/ þ mice (middle trace), which was normalized after treatment with rapamycin (right trace) must be noted. (c) Summary of the amiloride-sensitive equivalent short-circuit currents (I sc-Amil-distal colon ) in the distal colon of wt (open bar), APC Min/ þ (black bar) and rapamycin-treated APC Min/ þ mice (gray bar). (d) Similarly, a summary bar graph is shown of the amiloride-sensitive equivalent short-circuit currents (I sc-Amil-proximal colon ) in the proximal colon. Student's t-tests were used for statistical analyses (number of mice measured per group in parentheses; error bars ¼ s.e.m.; *Po0.05 versus untreated controls; # Po0.05 versus untreated APC Min/ þ ). APC, adenomatous polyposis coli; wt, wild type.
Rapamycin suppresses neoplasia in APC Min/ þ mice GE Koehl et al We conducted an in-depth analysis regarding the potential effects of rapamycin on oncogenic ion channels. Indeed, a substantial body of evidence exists for the oncogenic function of voltage-gated (Kv) and Ca 2 þ -activated (BK) K þ channels in colonic cancer and other tumors (Yao and Kwan, 1999; Pardo et al., 1999; Pardo et al., 2005; Ousingsawat et al., 2007; Ousingsawat et al., 2008) . K þ channels control proliferation by controlling cell cycle and essential homeostatic parameters, such as intracellular Ca 2 þ , pH and cell volume (Schreiber, 2005) . APC Min/ þ animals show overexpression of several members of the Eag family of Kv channels, as well as of BK channels. Erg channels are activated by Akt (Zhang et al., 2003) and confer greater malignancy to patients with leukemia (Pillozzi et al., 2007) . Moreover, mutations in the APC gene alter cell cycling (Dikovskaya et al., 2007) , and as Eag family channels are cell cycle regulated (Wonderlin and Strobl, 1996) , it is likely that these changes affect their activity. In this study, Eag family channels, Erg1 and Elk1, were upregulated in the colon of APC Min/ þ mice, but rapamycin treatment reduced the level of upregulation toward normalization. The BK channel subunits, BK b1 and BK b4 , were also found to be upregulated in APC Min/ þ mice. Both subunits increase Ca 2 þ and estradiol sensitivity and thereby increase BK activity (Valverde et al., 1999) . Moreover, upregulation of Akt may further increase the activity of Ca 2 þ -activated K þ channels, as membrane trafficking of BK channels was shown to be enhanced by Akt in a phosphoinositide-3 kinasedependent manner in the intestinal epithelium . Expression and activity levels of these oncogenic K þ channels, which are likely to contribute to malignancy in FAP patients and APC Min/ þ animals, were also largely reduced by rapamycin to normal levels. Finally, we examined the enhanced amiloride-sensitive Na þ absorption in the colon of APC Min/ þ animals, which is related to the possible upregulation of b-and g-subunits of ENaC. Interestingly, a previous study on fetal lung epithelia showed a pronounced increase in ENaC expression, which relied on the eukaryotic translation initiation factor eIF4E and activation of the mTOR pathway (Otulakowski et al., 2007) . In this study, treatment with rapamycin led to a remarkable downregulation of ENaC expression and Na þ absorption by the colonic epithelium. Given the well-described role of oncogenic ion channels for proliferation and development of cancer, normalization of oncogenic K þ channels by rapamycin represents a novel mechanism by which rapamycin may be capable of inhibiting tumor growth. 
Rapamycin suppresses neoplasia in APC
Min/ þ mice GE Koehl et al In conclusion, this study is supportive of clinical trials aimed at reducing polyp formation in FAP. Importantly, our experiments in APC Min/ þ mice suggest that low, non-bolus-type doses of rapamycin can be effective in the long term and therefore regimens can be designed to administer the drug with minimalized side effects. As different mTOR inhibitors are approved for long-term, indefinite use in clinical organ transplantation, it is not unreasonable to suggest their potential use to prevent disease progression in FAP patients. Furthermore, our experiments expose a novel mechanism by which rapamycin can potentially inhibit tumor growth through restoration of normal ion channel activity.
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